This inventor holds 2 USPTO granted patents and 5 published patent applications. Top assignee: Genentech, Inc.. Active years: 2025-2026.
Company Filing History:
Years Active: 2025-2026
Title: Iris Tranthuyngan To: Innovator in Biopharmaceuticals
Introduction
Iris Tranthuyngan To is a notable inventor based in South San Francisco, CA (US). She has made significant contributions to the field of biopharmaceuticals, particularly in the treatment of CD20-positive proliferative disorders. With a total of 2 patents, her work is paving the way for innovative therapies in this area.
Latest Patents
Iris's latest patents include groundbreaking methods for treatment with anti-CD20/anti-CD3 bispecific antibodies and anti-CD79B antibody drug conjugates. One of her notable inventions focuses on the treatment of subjects with CD20-positive cell proliferative disorders by administering a combination of mosunetuzumab and polatuzumab vedotin. This innovative approach aims to enhance treatment efficacy for patients suffering from these conditions.
Career Highlights
Iris is currently employed at Genentech, Inc., where she continues to develop and refine her innovative ideas. Her work is characterized by a commitment to advancing medical science and improving patient outcomes through targeted therapies.
Collaborations
Iris collaborates with esteemed colleagues, including Carol Elaine O'hear and Hong Wang, who contribute to her research and development efforts. These collaborations enhance the quality and impact of her work in the biopharmaceutical sector.
Conclusion
Iris Tranthuyngan To is a prominent figure in the field of biopharmaceuticals, with a focus on innovative treatments for CD20-positive proliferative disorders. Her contributions through patents and collaborations are making a significant impact in the medical community.